Arrowstreet Capital Limited Partnership Boosts Position in IQVIA Holdings Inc. $IQV

Arrowstreet Capital Limited Partnership boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 0.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 962,139 shares of the medical research company’s stock after acquiring an additional 7,236 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in IQVIA were worth $216,876,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Eagle Rock Investment Company LLC raised its holdings in IQVIA by 33.6% in the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after buying an additional 11,657 shares during the period. EDENTREE ASSET MANAGEMENT Ltd purchased a new stake in IQVIA in the 3rd quarter valued at about $7,368,000. AMG National Trust Bank purchased a new stake in IQVIA during the third quarter worth about $3,713,000. Citigroup Inc. increased its stake in IQVIA by 108.2% during the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock worth $173,830,000 after purchasing an additional 475,557 shares during the period. Finally, Picton Mahoney Asset Management increased its stake in IQVIA by 3,086.9% during the third quarter. Picton Mahoney Asset Management now owns 48,824 shares of the medical research company’s stock worth $9,275,000 after purchasing an additional 47,292 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on IQV shares. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a research note on Friday, March 6th. Truist Financial cut their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Mizuho set a $215.00 price objective on IQVIA in a research report on Monday, February 23rd. Finally, HSBC set a $210.00 price objective on IQVIA in a research report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Buy” and an average target price of $224.13.

IQVIA Stock Performance

Shares of IQV opened at $181.10 on Monday. The stock has a 50 day moving average price of $173.56 and a 200 day moving average price of $193.44. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a market capitalization of $30.23 billion, a price-to-earnings ratio of 22.44, a price-to-earnings-growth ratio of 1.56 and a beta of 1.21. IQVIA Holdings Inc. has a 52-week low of $153.01 and a 52-week high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts predict that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its board has authorized a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.